ADL BIONATUR SOLUTIONS, S.A. Inactive Instrument
ADL Bionatur Solutions, S.A. Stock BME
Equities
Biotechnology & Medical Research
| Sales 2022 | 2.96M 3.16M 4.32M | Sales 2023 | 3.91M 4.18M 5.71M | Capitalization | 22.85M 24.43M 33.4M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.07M -1.46M | Net income 2023 | 1M 1.07M 1.46M | EV / Sales 2022 | 6.72 x |
| Net Debt 2022 | 7.45M 7.96M 10.88M | Net Debt 2023 | 3.72M 3.98M 5.44M | EV / Sales 2023 | 6.8 x |
| P/E ratio 2022 |
-6.41
x | P/E ratio 2023 |
14.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.46% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 60 | 19-10-31 | |
Javier Uría
COO | Chief Operating Officer | - | - |
| Chief Tech/Sci/R&D Officer | - | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | - | - | |
| Director/Board Member | - | - | |
John Dixon
BRD | Director/Board Member | 68 | - |
Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Firmâs main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
